Kristina Masson

Dr. Kristina Masson is Acrivon's co-founder and has served as Executive Vice President, Business Operations since August 2022, as President, CEO and Site Head of the company's Swedish research subsidiary Acrivon AB, and as a member of the Board since March 2018; she previously served as Senior Vice President, Operations from March 2018 to August 2022. In 2016 she founded OncoSignature AB, which she led until its acquisition by Acrivon AB in March 2018. She was previously a Principal Scientist at Merrimack Pharmaceuticals and a post-doctoral fellow in the Golub lab at the Broad Institute of MIT and Harvard. Dr. Masson received her M.Sc. and Ph.D. from Lund University and an Executive M.B.A. from the MIT Sloan School of Management. She also serves on the board of Aqilion AB.